jRCT2061260009招募中不适用
A Multicenter, Investigator-Initiated Clinical Trial Comparing the Efficacy and Safety of a Novel BRT Regimen (High-Dose Glucocorticoids, Baricitinib, Rituximab, and Tacrolimus) With Standard Therapy in Patients With Anti-MDA5 Antibody-Positive Dermatomyositis With Multiple Poor Prognostic Factors (Phase 2)
未提供0 个研究点目标入组 44 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 80age old not（—）
- 性别
- All
入选标准
- •This study is intended for participants who meet all of the following inclusion criteria.
- •Patients who meet both criteria A) and B) of MDA5-DM
- •A) Positive for anti-MDA5 antibodies
- •B) Have any of the following
- •a) Skin symptoms characteristic of dermatomyositis (Gottron's sign, heliotrope rash, periungual erythema, etc.)
- •b) Dermatopathological findings consistent with dermatomyositis
- •Patients with rapidly progressive ILD within 3 months of the onset of symptoms who meet both criteria (1) and (2) below
- •(1) Meet at least one of the following respiratory criteria
- •Increased respiratory rate (>= 20 breaths/min)
- •A decrease of 10% or more from the baseline %FVC
- •An increase of 15 mmHg or more in resting P[A-a]O2 from the baseline, or a decrease of 3% or more in SpO2 from the baseline
- •A decrease in SpO2 of 4% or more from the resting level during a 6-minute walk test
- •SpO2 < 94%, or SpO2/FiO2 ratio (S/F ratio) < 315
- •PaO2 < 60 mmHg, or PaO2/FiO2 ratio (P/F ratio) < 300
- •(2) Meets the following criteria regarding imaging tests
- •Findings of acute exacerbation of interstitial pneumonia on chest HR-CT
- •Patients with at least one of the following poor prognostic factors A) through G)
- •A) Anti-MDA5 antibody titer >= 500 Index
- •B) Age >= 60 years
- •C) SpO2 < 95% (room air)
- •D) CRP >= 1 mg/dL
- •E) Ferritin >= 500 ng/mL
- •F) KL-6 >= 1000 IU/mL
- •G) LDH >= 355 U/L
- •Patients with no prior treatment history with JAK inhibitors, including rituximab (recombinant) and baricitinib, for MDA5-DM
- •Patients who have completed methylprednisolone (mPSL) pulse therapy for MDA5-DM within one week prior to the start of Cycle 1 Day 1 (C1D1) of this clinical trial, and who have not yet received intravenous cyclophosphamide
- •Patients aged 18 years or older but under 80 years who have provided written informed consent to participate in the trial of their own free will
- •If it is difficult to obtain consent directly from the patient at the time of consent acquisition, consent to participate in the trial may be obtained from a surrogate using the informed consent document.
排除标准
- •Patients with MDA5-negative DM-ILD
- •Patients with conditions other than MDA5-DM, such as severe emphysema or concurrent malignancies, who have a poor prognosis regardless of control of the ILD
- •Patients with a history of severe hypersensitivity or anaphylaxis to any of the following: rituximab (recombinant), baricitinib, tacrolimus, or cyclophosphamide; to any component of these drugs; or to products derived from mouse proteins
- •Patients who are positive for one or more of the following: HBs antigen, HBs antibody, HBc antibody, or HCV antibody
- •However, patients meeting the following criteria (1) and (2) may be enrolled.
- •(1) Patients who are positive for HBs antibody or HBc antibody, provided that HBV-DNA quantification is negative (below the detection limit) and appropriate monitoring can be conducted in accordance with the "Guidelines for the Treatment of Hepatitis B" published by the Japan Society of Hepatology
- •For patients who are HBs antibody-positive and whose vaccination history can be confirmed via medical records, HBV-DNA testing is not required.
- •If testing was performed within 3 months prior to obtaining consent, those results may be accepted.
- •(2) Patients who are HCV antibody-positive, provided that HCV-RNA quantification is negative (below the detection limit)
- •Patients with active tuberculosis
- •However, patients who are IFN-gamma release assay (IGRA) positive or have an inconclusive result at the time of screening may be enrolled if they meet all of the following conditions (1) and (2).
- •(1) Active tuberculosis has been ruled out by chest X-ray, CT, or other imaging
- •(2) Appropriate treatment for latent tuberculosis has been initiated in accordance with domestic guidelines at least 3 weeks prior to the start of administration of the investigational drug
- •Patients diagnosed with HIV infection
- •Patients with severe infections (e.g., sepsis)
- •Patients with a white blood cell count of less than 2,500/mm3
- •Patients with a neutrophil count of less than 1,000/mm3
- •Patients with a lymphocyte count of less than 500/mm3
- •Patients with a hemoglobin level of less than 8 g/dL
- •Patients with a platelet count of less than 10.0 x 10^4/uL
- •Patients on dialysis or with severe renal impairment (eGFR < 30 mL/min/1.73 m2)
- •Patients showing signs of liver dysfunction, with either AST or ALT levels exceeding five times the upper limit of the facility's reference range
- •Cardiac: Patients with a left ventricular ejection fraction (LVEF) of less than 50%, or patients with an LVEF of 50% or higher who have heart disease classified as NYHA Class III or higher, or who have had a Grade 3 or higher myocardial infarction, arrhythmia, or angina within one year prior to enrollment
- •Patients with concurrent malignant tumors or a history of malignant tumors within the past 5 years
- •Pregnant women, patients who may be pregnant, patients of either sex who wish to conceive, or patients who are breastfeeding
- •Patients for whom hospitalization during the administration period of rituximab (recombinant) is difficult
- •Patients whom the principal investigator or sub-investigator determines are unable or have difficulty taking the investigational drug appropriately
- •Other patients whom the principal investigator or sub-investigator determines are unsuitable for participation in this clinical trial
研究者
相似试验
招募中
不适用
A Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of the Toric Intraocular Lens N3T in Cataract Patients with Corneal AstigmatismCataract with corneal astigmatismjRCT204225021965
招募中
不适用
An Investigator-initiated, multicenter, single-arm, open-label study of scleral lens (AL-01) in perticipants with corneal astigmatism inadequate correction to spectacles or existing contact lens (SLICK)corneal astigmatismjRCT203225086325
招募中
不适用
Phase III study of KD2-396Prevention of pertussis, diphtheria, tetanus, poliomyelitis(polio), Hib infection, and hepatitis BjRCT2031250804540
招募中
不适用
A Study of Quabodepistat-containing Regimen for the Treatment of Drug-resistant Pulmonary Tuberculosis (QUANTUM-TB).Pulmonary Multidrug-resistant TuberculosisjRCT2031260045532
招募中
不适用
Investigator-Initiated Phase II Clinical Trial of MA-5 for Mitochondrial Disease
An Exploratory, Investigator-Initiated Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MA-5 in Patients with Mitochondrial Disease and Hearing LossMitochondrial disease with hearing lossjRCT203125050515